Health

FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilar Otulfi (ustekinumab-aauz)

DailyTrendDailyTrend
May 21, 2025 - 17:00
 0  0
FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilar Otulfi (ustekinumab-aauz)
LAKE ZURICH, Ill., May 19, 2025 – Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S Food and Drug Administration (FDA) designated Otulfi (ustekinumab-aauz) as an interchangeable biosimilar to the...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

How Medicaid Cuts Could Force Disabled Americans Into Institutions

How Medicaid Cuts Could Force Disabled Americans Into I...

DailyTrend Aug 20, 2025  0  0

A $45 Treatment Can Save a Starving Child. US Aid Cuts Have Frozen the Supply

A $45 Treatment Can Save a Starving Child. US Aid Cuts ...

DailyTrend Aug 16, 2025  0  0

What to Know About Plague After a New Case in California

What to Know About Plague After a New Case in California

DailyTrend Aug 22, 2025  0  0

Are Marathons and Extreme Running Linked to Colon Cancer?

Are Marathons and Extreme Running Linked to Colon Cancer?

DailyTrend Aug 20, 2025  0  0

Congo Has Astronomical Rates of Sexual Violence. Now Vi...

DailyTrend Aug 22, 2025  0  0

Sport Psychology Tips for Everyday Life

Sport Psychology Tips for Everyday Life

DailyTrend Aug 21, 2025  0  0